Search Press releases Keywords From To 25 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 Read More 24 Sep 2024 Transparency notification BlackRock, Inc. Read More 24 Sep 2024 UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 Read More 23 Sep 2024 UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis Read More 9 Sep 2024 New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease Read More Pagination First page Previous page Previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Page 11 of 69 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
